Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target increased by research analysts at Royal Bank of Canada from $1,252.00 to $1,260.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an "outperform" rating on the biopharmaceutical company's stock. Royal Bank of Canada's price objective points to a potential upside of 24.27% from the stock's previous close.
Several other analysts have also issued reports on REGN. Guggenheim increased their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. TD Cowen lifted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a "buy" rating in a research report on Tuesday, July 23rd. Canaccord Genuity Group restated a "buy" rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Leerink Partnrs cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Finally, BMO Capital Markets restated an "outperform" rating and set a $1,300.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $1,119.00.
Read Our Latest Stock Report on REGN
NASDAQ REGN traded down $0.66 during midday trading on Friday, hitting $1,013.93. The company had a trading volume of 211,871 shares, compared to its average volume of 486,961. The stock has a market cap of $111.72 billion, a price-to-earnings ratio of 29.95, a P/E/G ratio of 3.56 and a beta of 0.12. Regeneron Pharmaceuticals has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The firm has a fifty day simple moving average of $1,126.96 and a two-hundred day simple moving average of $1,036.61. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts' consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the company earned $8.79 earnings per share. The company's revenue was up 12.3% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.
In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company's stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the firm's stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,033 shares of company stock worth $9,399,345. 7.48% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the company. MRA Advisory Group bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $455,000. Park Avenue Securities LLC raised its position in shares of Regeneron Pharmaceuticals by 7.6% during the third quarter. Park Avenue Securities LLC now owns 1,889 shares of the biopharmaceutical company's stock worth $1,986,000 after purchasing an additional 134 shares during the period. Czech National Bank lifted its holdings in shares of Regeneron Pharmaceuticals by 7.0% during the third quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company's stock valued at $22,725,000 after purchasing an additional 1,405 shares during the last quarter. Greater Midwest Financial Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 8.8% in the 2nd quarter. Greater Midwest Financial Group LLC now owns 2,502 shares of the biopharmaceutical company's stock valued at $2,894,000 after purchasing an additional 203 shares during the period. Finally, Centaurus Financial Inc. purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $118,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.